Premier Alternatives

Dualitas Therapeutics

South San Francisco, CA · Founded 2023 · Privately Held (backing)

Developer of a bispecific antibody therapeutics platform designed for addressing immunology and inflammation. Dualitas Therapeutics is based in South San Francisco, CA and was founded in 2023. It was valued at $87 million at its early-stage round in Sep 2025, the last priced event on record. It has raised $65 million across 1 recorded round; the latest was a $32.6 million early-stage round in Jul 2025.

PMV mark · valuation
$87.0M
Oct 2026
Priced at
its early-stage round
Sep 2025
Total raised
$65.0M
Last round
Early Stage VC
Jul 2025

Dualitas Therapeutics key facts

as of Oct 2026
  • Developer of a bispecific antibody therapeutics platform designed for addressing immunology and inflammation.
  • Dualitas Therapeutics is valued at approximately $87.0M as of Oct 2026, set at its early-stage round, Sep 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $65.0M across 1 recorded rounds; the latest was Early Stage VC ($32.6M) in Jul 2025.
  • Notable investors include Qiming Venture Partners, Alexandria Venture Investments, SV Health Investors, Versant Ventures, Chugai Venture Fund — 6 tracked in total.
  • Dualitas Therapeutics has filed 1 Form D with the SEC, most recently Nov 2025 ($32.6M sold to 7 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$87.0M

Valued at $87.0M at its early-stage round, Sep 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Dualitas Therapeutics with a free account
  • ·Watch Dualitas Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Dualitas Therapeutics funding rounds

1 rounds
Jul 2025Early Stage VC$32.6MSEC filing▮
Full funding history →

Dualitas Therapeutics valuation

Dualitas Therapeutics was valued at $87 million at its early-stage round in Sep 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Dualitas Therapeutics raised?

Dualitas Therapeutics has raised $65 million in total; 1 of its rounds is on record. The largest on record was a $32.6 million early-stage round in Jul 2025.

Dualitas Therapeutics has filed 1 Form D with the SEC, most recently in Nov 2025 ($32.6 million sold to 7 investors).

Dualitas Therapeutics investors

6 investors are on record for Dualitas Therapeutics, including Qiming Venture Partners, Alexandria Venture Investments, SV Health Investors and Versant Ventures. The early-stage round in Jul 2025 drew 7 investors.

About Dualitas Therapeutics

Developer of a bispecific antibody therapeutics platform designed for addressing immunology and inflammation. The company's platform integrates discovery and rapid candidate optimization to identify novel bispecific antibody candidates by functionally screening the entire cell surface, enabling patients with immune and inflammatory diseases to access therapies with the potential for greater pharmacologic activity and more meaningful clinical benefit.

Sector
Healthcare
HQ
South San Francisco, CA, United States
Founded
2023
Employees
15
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.